Market Herald logo


Be the first with the news that moves the market

Immuron reported a third-quarter 66 percent increase in sales. Immuron is a Biopharmaceutical company focused on digestive supplements.

Q3 global sales reaped AUD$616,000 compared to 2018’s Q3 Global sales of $371,000. Year-to-date sales at 31 March reached AUD1.7M, a 23 percent increase.

Q3 sales of the company’s product most popular product, Travelan, surged 73 percent in Australia. US sales of Travelan were similar at 60 percent growth.

The company recently began airing an ad spotlight with Chemist Warehouse for Travelan.

Travelan has also been featured in a partnership with US travel medicine network Passport Health.

Immuron CEO Gary Jacob says the company will focus on continuing the expansion of Travelan sales growth.

“[Travelan sales] within existing markets, coupled with our re-entry into Canada puts us in a strong position for continued growth,” he said.

Immuron rose 16.7 percent in the ASX today.

Please see the announcement attached

IMC by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Nuix (NXL) - Outgoing Group CEO Rod Vawdrey

" Nuix (ASX:NXL) appoints new members to its board

Nuix (NXL) has seen a company reshuffle, appointing new members to its board.

" AL3D (ASX:AL3) sells Arcemy 3D printer to University of Queensland

AL3D Limited (AL3) has sold one of its Arcemy WAM printing units to the University of Queensland (UQ) for around $400,000.

" EP&T Global (ASX:EPX) forecasts 85pc ARR growth for FY22

EP&T Global (EPX) expects the company’s annualised recurring revenue (ARR) to grow by 85 per cent in the 2022 financial year.